Background
==========

Chronic obstructive pulmonary disease (COPD) is a preventable disease characterized by partially irreversible airflow limitation due to progressive inflammation of the lower airways. Smoking is the main risk factor \[[@B1],[@B2]\]. COPD is a common disease whose age-standardized mortality rate increased during the 1990s, and it is predicted to be a major cause of death worldwide during the next two decades \[[@B3]-[@B5]\]. With such a high burden on the healthcare system, emphasis on better diagnosis and management of the disease must be achieved and reliable epidemiological data on the prevalence and severity of COPD and its exacerbations are crucial to guide decisions. Indeed, international comparisons of COPD prevalence, mortality rates and management of acute exacerbations may help to identify the most effective healthcare systems in this setting.

Differences in healthcare systems and criteria make it difficult to compare data across different countries \[[@B6],[@B7]\]. Efforts have been made to standardize prevalence estimates through the international Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) and Burden of Obstructive Lung Disease (BOLD) study initiatives, for example \[[@B8],[@B9]\]. To obtain a representative picture of the epidemiological situation in Europe and what has been achieved so far, we reviewed the literature on COPD in Europe, focusing on prevalence, severity, exacerbations and mortality. The goal of the study was to examine the differences in these epidemiological estimates across countries in light of the differences in methods used from one study to another. Therefore, we collected the following features associated with the epidemiological estimates reported: publication date, type of population, sample size and definitions used (for example, severity scale used, exacerbation definition used). This review strongly suggests that establishing reporting guidelines dedicated to COPD studies may constitute a major contribution to enhancing the value of COPD research and management by facilitating comparisons between studies.

Methods
=======

Document search
---------------

We sought documents on the prevalence, mortality, severity and exacerbations of COPD in the Science Citation Index database via the Web of Science (WOS) (Thomson Reuters, New York, NY, USA). The search was limited to documents published between 1991 and 2009, focusing on the epidemiology of COPD (prevalence, severity, exacerbations and mortality) in different populations (general population, patients followed up by a general practitioner and/or chest specialist, ambulatory patients and inpatients). We also extracted data from the European statistical database (Eurostat) \[[@B10]\].

WOS was queried using a four-step strategy as follows:

1\. TS = COPD or chronic obstructive pulmonary disease or chronic bronchitis

2\. TS = Prevalence or severity or mortality or exacerbation

3\. TI = Cancer

4\. (2 AND 1) NOT 3

where TI is a term search limited to the title of the document and TS is a term search in the title, abstract and keywords.

Document triage and selection
-----------------------------

We applied the following exclusion criteria to the WOS documents obtained using the above strategy: We excluded documents concerning non-European Union countries, documents that were not original articles or reviews and documents with WOS subject categories not relevant to this study (for example, biophysics, biochemistry, microbiology, psychology, social issues, bioinformatics, toxicology). Finally, document eligibility was completed by deeper examination of the remaining articles. Articles not dealing primarily with the epidemiology of COPD (that is, prevalence, severity, mortality, exacerbations) or not specifying sufficiently important definitions related to the epidemiological estimates (for example, diagnostic tests used and target population, including inclusion and exclusion criteria) were excluded from the review. A comparable search in the MEDLINE database via the PubMed interface did not retrieve any additional documents.

The Eurostat database was used to extract age-standardized COPD mortality rates (deaths per 100,000 inhabitants) for 2007 by using code J40-47 (death as a result of lower respiratory tract disease) and by excluding codes J45 and J46 (death as a result of asthma). Death as a result of bronchiectasis (J47) was not excluded, because the corresponding number of cases was considered minor.

Analysis of the collected information
-------------------------------------

Considering each of the reported epidemiological estimates (prevalence, severity, exacerbations and mortality), we collected several associated features: publication date, type of population under study, sample size and definitions used (for example, severity scale used, exacerbation definition used). We then listed each estimate report with its associated feature described above to obtain a picture of the variability of estimates across countries in light of the methodological differences between studies.

Results
=======

Information included in the review
----------------------------------

The process for including final information used in the review is detailed in Figure [1](#F1){ref-type="fig"}. The initial literature search resulted in 7,302 WOS documents, and after applying the exclusion criteria and eligibility steps, 65 articles (61 in English, 3 in Spanish \[[@B11]-[@B13]\] and 1 in French \[[@B14]\]) were finally included in the study (Figure [1](#F1){ref-type="fig"}). COPD mortality data in the Eurostat database were available for 21 countries of the European Union.

![**Flowchart of the process for collecting information included in the review**.](1741-7015-9-7-1){#F1}

Prevalence
----------

COPD prevalence data can be categorized into four types according to the criteria used to define the disease (Table [1](#T1){ref-type="table"}; see also a graph of these data in Additional file [1](#S1){ref-type="supplementary-material"}, Figure A1), namely, symptoms \[[@B15]-[@B17]\], physician reports \[[@B18]-[@B23]\], spirometry \[[@B8],[@B11]-[@B13],[@B24]-[@B39]\] and models \[[@B40]-[@B42]\].

###### 

COPD prevalence data^a^

  Criteria used to define COPD              Country (sample size)    Study population           **Age**^**b**^**(yr)**   Prevalence (%)
  ----------------------------------------- ------------------------ -------------------------- ------------------------ ----------------
  Symptoms^c^                                                                                                            
   Cerveri *et al.*, 2003 \[[@B15]\]        Italy (18,645)           General population         20-44                    9.5
   Huchon *et al.*, 2002 \[[@B16]\]         France (14,076)          General population         ≥25                      4.1
   Cerveri *et al.*, 2001 \[[@B17]\]        16 countries (14,819)    General population         20-44                    2.6
                                                                                                                         
  Physician reports                                                                                                      
   Cazzola *et al.*, 2009 \[[@B18]\]        Italy (15,229)           General population         NS                       2.5
   Schirnhofer *et al.*, 2007 \[[@B19]\]    Austria (1,258)          General population         ≥40                      5.6
   Montnemery *et al.*, 2006 \[[@B20]\]     Sweden (3,692)           General population         20-59                    3.6
   Hedman *et al.*, 1999 \[[@B21]\]         Finland (3,102)          General population         18-65                    3.7
   Montnemery *et al.*, 1998 \[[@B22]\]     Sweden (8,469)           General population         20-59                    4.6
   Lundback *et al.*, 1991 \[[@B23]\]       Sweden (6,610)           General population         35-66                    4.1
                                                                                                                         
  Functional respiratory tests                                                                                           
   Miravitlles *et al.*, 2009 \[[@B24]\]    Spain (4,274)            General population         56.6 (10.7)              10.2
   Van Durme *et al.*, 2009 \[[@B25]\]      Netherlands (7,983)      General population         ≥55                      11.6
   Hansen *et al.*, 2008 \[[@B26]\]         Denmark (4,757)          General population         45-84                    12.0
   Bednarek *et al.*, 2008 \[[@B27]\]       Poland (1,960)           Primary care               56.7 (11.6)              9.3
   Roche *et al.*, 2008 \[[@B28]\]          France (4,764)           Health prevention center   59.9 (10.1)              2.6
   Buist *et al.*, 2007 \[[@B8]\]           Austria (1,258)          General population         ≥40                      26.1^d^
                                            Germany (683)                                                                13.3
                                            Poland (526)                                                                 22.1
                                            Norway (638)                                                                 18.8
   Shahab *et al.*, 2006 \[[@B29]\]         United Kingdom (8,215)   General population         55.5 (13.5)              13.3
   Stavem *et al.*, 2006 \[[@B30]\]         Norway (1,619)           Occupational cohort        49.8 (5.5)               16.4
   Sichletidis *et al.*, 2005 \[[@B31]\]    Greece (6,112)           General population         21-80                    5.6
   Murtagh *et al.*, 2005 \[[@B32]\]        Ireland (2,484)          General population         53.3 (8.6)               6.3
   Tzanakis *et al.*, 2004 \[[@B33]\]       Greece (888)             General population         ≥35                      8.4
   Hasselgren *et al.*, 2001 \[[@B34]\]     Sweden (4,814)           General population         43 (14.8)                2.1
   Peña *et al.*, 2000 \[[@B35]\]           Spain (3,978)            General population         40-69                    9.1
   Viegi *et al.*, 2000 \[[@B36]\]          Italy (1,727)            General population         ≥25                      11.0 or 18.3
   Jaen *et al.*, 1999 \[[@B11]\]           Spain (497)              General population         20-70                    7.2
   Dickinson *et al.*, 1999 \[[@B37]\]      United Kingdom (353)     General population         68.25                    9.9
   Marco Jordán *et al.*, 1998 \[[@B12]\]   Spain (460)              General population         40-60                    6.8
   Renwick & Connolly, 1996 \[[@B38]\]      United Kingdom (783)     General practitioner       66.1                     9.0
   Brotons *et al.*, 1994 \[[@B13]\]        Spain (642)              General population         35-65                    6.4
   Bakke *et al.*, 1991 \[[@B39]\]          Norway (1,275)           General population         42 (16.1)                4.5
                                                                                                                         
  Models                                                                                                                 
   Peabody *et al.*, 2005 \[[@B40]\]        Spain                    Total population           ≥30                      6.2
                                            Norway                                                                       6.3
                                            Poland                                                                       6.7
   Feenstra *et al.*, 2001 \[[@B41]\]       Netherlands              Total population           ≥20                      1.5
   Stang *et al.*, 2000 \[[@B42]\]          Spain                    Total population           ≥45                      10.3
                                            Italy                                                                        11.1
                                            France                                                                       10.4
                                            United Kingdom                                                               15.0

^a^Prevalence estimates are based on symptoms (cough and sputum at least 3 months each year), physician reports, functional respiratory tests (FEV~1~/FVC ratio \<70%, FEV~1~\<80% of predicted, FEV~1~/FVC ratio \<65%, FEV~1~/FVC ratio \<70% or FEV~1~/FVC ratio \<88% (male)/89% (female)) and models (general population). ^b^Age was reported in various ways distinguished here as follows: \"≥ x\", minimum age; \"x\" or \"x (y)\", mean age or mean age (SD); \"x-y\", age range i.e. min-max. ^c^These patients had chronic bronchitis. ^d^These data are also reported in Schirnhofer *et al.*, 2007 \[[@B19]\]. Abbreviations used: COPD, chronic obstructive pulmonary disease; NS, not specified; FEV~1~, maximum expiratory volume in 1 second; FVC, forced vital capacity.

Surveys based on symptoms (cough and expectoration on most days for as much as three months per year and for at least two successive years) were used to estimate the prevalence of chronic bronchitis (initial stage of COPD). This prevalence ranged from 2.6% to 9.5% in adults under 44 years of age \[[@B15]-[@B17]\]. Major variability was noted across European countries, with prevalence rates ranging from 0.7% to 9.7% (median, 2.6%) in a study covering 16 countries \[[@B17]\]. There were also significant regional differences within a given country \[[@B17]\]. The prevalence of chronic bronchitis is reported to be significantly lower among women than among men in all countries (2.8% versus 3.7%; *P*\< 0.001) \[[@B17]\]. The prevalence increased gradually from nonsmokers to \"moderate-heavy\" smokers (≥15 packs-yrs) and from higher socioeconomic classes to the unemployed and blue-collar workers \[[@B15]-[@B17]\].

Studies \[[@B18]-[@B23]\] based on diagnoses of chronic bronchitis by healthcare professionals have produced less varying results, with prevalence rates ranging from 3.7% to 5.6% among adults. In studies based on respiratory function, such as the ratio of the maximum expiratory volume in 1 second (FEV~1~) over forced vital capacity \[[@B8],[@B11]-[@B13],[@B24]-[@B39]\] or the difference between measured and predicted FEV~1~\[[@B37]\], the prevalence ranged from 2.1% \[[@B37]\] to 26.1% \[[@B8],[@B19]\], but this large range may be attributed in part to the different types of population in which the prevalence was estimated. However, differences in population characteristics only partly explain the variability of the reported prevalence estimates. Even if one limits the analysis to patients over 40 years of age, the prevalence of the COPD still varies widely, from 4.5% in Norway \[[@B39]\] to 26.1% in Austria \[[@B8]\]. The functional criteria used to diagnose COPD also vary from one study to another, depending on the classification used: American Thoracic Society (ATS) \[[@B43]\], British Thoracic Society (BTS) \[[@B44]\], European Respiratory Society Task Force (ERS) \[[@B45]\], or Global Initiative for Chronic Obstructive Lung Diseases (GOLD) \[[@B46]\]. In the international BOLD study \[[@B8]\], based on the general population and on the current GOLD guidelines, the prevalence estimates issued from the 12 countries under study significantly varied from one site to another, with differences between men and women likely to reflect gender smoking rates. Considering the sites from the five European countries participating in the BOLD study, prevalence estimates ranged from 13.3% in Germany to 26.1% in Austria. In all, six of the nine papers that used the definition of COPD proposed by the GOLD initiative refer to the general population \[[@B8],[@B19],[@B24]-[@B26],[@B29]\], and with respect to these data, the prevalence estimates range between 10.2% in Spain \[[@B24]\] and 26.1% in Austria \[[@B8]\].

Several authors have proposed model-based approaches for estimating COPD prevalence \[[@B40]-[@B42]\]. These models combine demographic data with smoking rates \[[@B40]-[@B42]\], data on respiratory function in the general population \[[@B40],[@B42]\] and other risk factors such as air pollution and low socioeconomic status \[[@B40]\]. In these studies, the prevalence varied from 1.5% to 15% in the general population, and a given model \[[@B42]\] applied to the population over 45 years of age in four European countries resulted in estimates varying from 10.3% in Spain to 15% in the United Kingdom.

Severity
--------

The reported epidemiology of COPD severity \[[@B8],[@B14],[@B27],[@B29],[@B33],[@B36],[@B47]-[@B57]\] depends on whether the analysis concerns the general population \[[@B8],[@B29],[@B33],[@B36],[@B47]-[@B50]\], patient follow-up by a general practitioner and/or chest specialist \[[@B14],[@B27],[@B51]-[@B54]\] or inpatients (Table [2](#T2){ref-type="table"}; see also a graph of these data in Additional file [2](#S2){ref-type="supplementary-material"}, Figure A2) \[[@B55]-[@B57]\]. Moreover, results were also reported according to various severity scales (Figure [2](#F2){ref-type="fig"}).

###### 

Severity of COPD^a^

                                                                                                         **Severity**^**c**^**(%)**                 
  ---------------------------------------------- ------------------------- --------------- ------------- ---------------------------- ------ ------ ------
  General population                                                                                                                                
                                                                                                                                                    
   Buist *et al.*, 2007 \[[@B8]\]                Austria (1,349)           GOLD 2006       ≥40           59.4                         35.2   5.4    
                                                 Germany (713)                                           55.3                         38.6   6.1    
                                                 Poland (603)                                            50.7                         40.7   8.6    
                                                 Norway (707)                                            55.8                         37.8   6.4    
   Shahab *et al.*, 2006 \[[@B29]\]              United Kingdom (8,215)    GOLD 2006       55.5 (13.5)   41.6                         43.9   14.5   
                                                                                                                                                    
   Lindberg *et al.*, 2006 \[[@B47]\]            Sweden (1,237)            GOLD 2006       46-77         57.0                         37.0   5.0    1.0
                                                                           BTS 1997                      65.0                         27.0   8.0    NA
                                                                                                                                                    
   De Marco *et al.*, 2004 \[[@B48]\]^d^         Belgium (1,122)           GOLD 2003       20-44         58.6                         41.4   ND     
                                                 Denmark (394)                                           56.4                         43.6   ND     
                                                 France (2,137)                                          66.7                         33.3   ND     
                                                 Germany (1,983)                                         64.8                         35.2   ND     
                                                 Italy (910)                                             69.4                         30.6   ND     
                                                 Ireland (454)                                           75.3                         24.7   ND     
                                                 Netherlands (1,362)                                     74.3                         25.7   ND     
                                                 Norway (969)                                            40.7                         59.3   ND     
                                                 Spain (1,942)                                           59.2                         40.8   ND     
                                                 Sweden (1,859)                                          79.3                         20.7   ND     
                                                 Switzerland (853)                                       76.3                         23.7   ND     
                                                 United Kingdom (1,198)                                  69.8                         30.2   ND     
                                                                                                                                                    
   Tzanakis *et al.*, 2004 \[[@B33]\]            Greece (888)              ERS 1995        ≥35           58.2                         25.6   16.2   NA
   Jansson *et al.*, 2002 \[[@B49]\]             Sweden (212)              BTS^e^          28-29         75.0                         25.0   0      0
                                                                                           43-44         46.6                         46.6   6.8    0
                                                                                           49-50         16.0                         64.0   12.0   8.0
                                                                                           58-59         15.4                         57.7   15.4   11.5
                                                                                           64-65         6.9                          29.3   41.4   22.4
                                                                                           73-74         14.3                         21.4   47.6   16.7
                                                                                           79-80         9.8                          34.2   48.8   7.3
   Viegi *et al.*, 2000 \[[@B36]\]               Italy (1,727)             ERS 1995        ≥25           81.0                         14.0   5.0    NA
                                                                           ATS 1995                      98.2                         1.8    0      NA
                                                                                                                                                    
                                                                           Clinical^f^                   86.1                         13.9          
                                                                                                                                                    
   Von Hertzen *et al.*, 2000 \[[@B50]\]^g^      Finland (7,217)                           ≥30           59.8                         34.1   6.1    NA
                                                                                                                                                    
  General practitioner and/or chest specialist                                                                                                      
   Izquierdo *et al.*, 2009 \[[@B51]\]           Spain (3,619)             GOLD 2006       67.0 (10.8)   20.1                         54.0   22.1   3.8
   Bednarek *et al.*, 2008 \[[@B27]\]            Poland (1,960)            GOLD 2006       56.7 (11.6)   30.6                         51.4   15.3   2.7
   Hoogendoorn *et al.*, 2006 \[[@B52]\]         Sweden (481)              GOLD 2006       65.5          30.0                         51.0   17.0   2.0
   Piperno *et al.*, 2005 \[[@B14]\]             France (3,411)            SPLF 1996       58.4 (9.9)    31.3                         50.2   18.5   NA
   Detournay *et al.*, 2004 \[[@B53]\]           France (255)              SPLF 1996       67.1          56.0                         27.0   17.0   NA
   Soriano *et al.*, 2000 \[[@B54]\]             United Kingdom (23,277)   Prescriptions   66.7 (15.5)   35.5                         56.4   8.1    NA
                                                                                                                                                    
  Hospital                                                                                                                                          
   Soler-Cataluña *et al.*, 2005 \[[@B55]\]      Netherlands (304)         GOLD 2006       71 (9)        6.6                          35.8   33.6   24.0
   Tsoumakidou *et al.*, 2004 \[[@B56]\]         Greece (67)               ERS 1995        69.0          0                            4.5    95.5   NA
                                                                           BTS 1997        69.5          1.5                          14.9   83.6   NA
                                                                           ATS 1995        67.6          4.5                          28.3   67.2   NA
                                                                                                                                                    
                                                                           GOLD 2001       69.5          0                            58.2   41.8   
   Kornmann *et al.*, 2003 \[[@B57]\]            Germany (1,434)           GOLD 2001       {55}          7.9                          73.0   19.1   

^a^COPD severity data are reported for the general population, inpatients, general practitioner reports, general practitioner and chest specialist reports or are taken from medical databases. ^b^Age was reported in various ways distinguished here as follows: \"≥ x\", minimum age; \"x\" or \"x (y)\", mean age or mean age (SD); \"x-y\", age range i.e. min-max; \"{x}\", median age. mean age (±SD); median age; age range, min-max. ^c^ERS 1995, ATS 1995, BTS 1995 and SPLF 1995 classifications define only three stages. ^d^In this study, based on the GOLD 2003 severity scale, the estimates for stage 0 defining patients at risk of COPD ranged from 51.7% in Switzerland to 89.8% in Spain. ^e^Patients with both FEV~1~/FVC \<70% and FEV~1~≥80% (considered as having COPD in the GOLD 2006 classification but not in the BTS 1995 classification) were also included in the study. ^f^Airway obstruction of any degree was defined by FEV~1~/FVC ratio \<70% and the severity of obstruction was graded according to the FEV~1~value: mild (FEV~1~≥70% of predicted) and moderate to severe (FEV~1~\<70% of predicted). ^g^Airway obstruction of any degree was defined by FEV~1~/FVC ratio \<80% and the severity of obstruction was graded according to the FEV~1~/FVC value: 70-79%, minimal to mild; 50-69%, moderate; \<50%, severe. Abbreviations used: COPD, chronic obstructive pulmonary disease; ERS 1995, European Respiratory Society 1995 classification; ATS 1995, American Thoracic Society 1995 classification; BTS 1995, British Thoracic Society 1995 classification; SPLF 1995, Société de Pneumonologie de Langue Française 1995 classification; GOLD 2001, GOLD 2003 and GOLD 2006, Global Obstructive Lung Disease 2001, 2003 and 2006 classifications; ND, not defined; NA, not applicable; FEV~1~, maximum expiratory volume in 1 second; FVC, forced vital capacity.

![**The most popular chronic obstructive pulmonary disease classifications: ERS, European Respiratory Society; ATS, American Thoracic Society; SPLF, Société de Pneumologie de Langue Française; BTS, British Thoracic Society; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume in 1 second**. ATS, BTS, ERS and SPLF classifications define three stages of severity between 0% and 100% (ATS and ERS) or 80% (BTS and SPLF) of predicted FEV~1~. The most recent classification is the GOLD classification, which was initially proposed in 2001 and has been modified twice, in 2003 and 2006. In 2003, the GOLD classification evolved from three to four stages plus a supplementary stage 0 defining patients at risk (that is, the presence of chronic cough and sputum, but no obstruction together with FEV~1~over forced vital capacity ratio \>70%; stage 0 is not shown in the figure), and stage 0 was not kept in the GOLD classification system in 2006.](1741-7015-9-7-2){#F2}

In general patient populations, early-stage disease predominates among people over 40 years of age, with rates of GOLD 2006 stage 1 disease (FEV~1~≥80% of predicted) and stage 2 disease (80% \< FEV~1~≤ 50% of predicted), respectively, ranging from 50.7% and 40.7% in Poland to 59.4% and 35.2% in Austria \[[@B8]\]. In a study based on the GOLD 2003 severity scale and on a younger population (ages 20 to 44 years), estimates substantially varied from one country to another: from 51.7% in Switzerland to 89.8% in Spain for stage 0 and from 3.4% in Italy to 16.8% in Denmark for stages 2 and 3. The authors had no clear explanation for these differences \[[@B48]\]. The proportion of advanced stages increases with age, peaking at age 60 years. Thus, in a Swedish study based on the BTS classification \[[@B49]\], the percentage of stage 4 disease, which was negligible below age 40 years, reached 22.4% at age 58 or 59 years before decreasing again to 7.3% at 73 or 74 years of age. This increase with age is observed in both men and women \[[@B8]\]. The relationship between tobacco consumption and GOLD stage 2 disease or higher was less clear, partly owing to interference by age \[[@B8]\]. Moderate forms of the disease are more frequent in cohorts of patients followed by general practitioners or specialists, with observed frequencies ranging from 27% to 56.4% \[[@B14],[@B27],[@B51]-[@B54]\].

Analyses of severity among COPD inpatients show, quite logically, more frequent advanced forms of the disease, with a dramatic decrease in the proportion of patients with mild COPD (reported proportions ranging from 0% to 7.9%). The existence of several severity scales leads to major variations in the reported epidemiology of COPD severity, even when considering a given type of population. Depending on whether the ERS, ATS, BTS or GOLD criteria are used (Table [2](#T2){ref-type="table"}), the percentage of early stages in the general population is, respectively, 80%, 98%, 65% and 55%, while advanced stages represent, respectively, 95%, 67%, 85% and 58% of cases among COPD inpatients \[[@B36],[@B47],[@B56]\].

In general, there is a relatively low variability in the severity estimates based on GOLD criteria and derived from a given type of population. For example, when considering the general population of patients who are at least 40 years old, the severity distributions of patients in Norway \[[@B8]\], Germany \[[@B8]\] and Sweden \[[@B47]\] are similar. In the same way, the severity distributions in patients recruited from general practitioners and/or specialists in Sweden \[[@B52]\] and Poland \[[@B27]\] are comparable.

Exacerbations
-------------

Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} list the 22 reports mentioning the frequency of COPD exacerbations in European patients according to severity stage \[[@B53],[@B55],[@B58]-[@B77]\]. The definition of exacerbation substantially varied from one study to another (Table [3](#T3){ref-type="table"}). The mean number of exacerbations per person and per year ranges from 0.6 to 3.5 \[[@B63],[@B72]\] according to the disease stage and the age group (Table [4](#T4){ref-type="table"}). Borg *et al.*\'s model \[[@B77]\], in which parametric values were derived from the literature, used mean frequencies of exacerbations of, respectively, 0.05 and 1.47 per person per year at GOLD stages 1 and 4. According to Soler-Cataluña *et al.*\[[@B55]\], 26% of very severely affected patients have at least three exacerbations per year compared to 0% of mildly affected patients. The number of exacerbations can be reduced by treatment \[[@B60],[@B66]\]. Exacerbations are usually categorized as mild (symptoms treated at home or easily tolerated), moderate (treatment in a hospital or affecting daily activity) or severe (specialist treatment or inability to work). More severe disease stages are associated with more severe exacerbations \[[@B60],[@B66]\]. In Borg *et al.*\'s model \[[@B77]\], the average frequencies of severe exacerbations are 0.01 and 0.33 per patient per year at GOLD stage 1 and GOLD stage 4, respectively. Such estimates have been confirmed by another observational study \[[@B55]\].

###### 

Exacerbation definitions^a^

  Diagnostic method                           Description of symptoms
  ------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment                                   
   Burge *et al.*, 2003 \[[@B58]\]^b^         Chest problem requiring treatment with oral corticosteroids and/or antibiotics as defined by the treating physician
   Calverley *et al.*, 2003 \[[@B59]\]        Worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids or both
   Jones *et al.*, 2003 \[[@B60]\]^b^         Chest problems requiring treatment with antibiotics and/or oral corticosteroids
   Andersson *et al.*, 2002 \[[@B61]\]        Increased dose of current treatment and/or treatment with antibiotics or systemic corticosteroids and/or general practitioner or outpatient visit or hospital admission
   Burge *et al.*, 2000 \[[@B62]\]^b^         Worsening of respiratory symptoms that required treatment with oral corticosteroids, antibiotics or both as judged by the general practitioner
  Symptoms                                    
   Effing *et al.*, 2009 \[[@B63]\]           Presence for at least 2 consecutive days of an increase in any two major symptoms or an increase in one major and one minor symptom
   Worth *et al.*, 2009 \[[@B64]\]            A complex of at least two respiratory adverse events with a duration of more than 3 days
   Schermer *et al.*, 2009 \[[@B65]\]         Episode with one or more subsequent unscheduled contacts with either a general practitioner or a chest physician because of worsening of respiratory symptoms
   O\'Reilly *et al.*, 2006 \[[@B66]\]^c^     Symptom-based: Symptom score of at least 2 for 2 consecutive days with no score for at least two of these symptoms in the previous 5 days Healthcare-based: Need to take antibiotics and/or oral corticosteroids for chest problem
   Wilkinson *et al.*, 2006 \[[@B67]\]        Not defined but specified as symptom-based
   Donaldson *et al.*, 2003 \[[@B68]\]        An increase in either two or more major symptoms or any one major symptom plus any minor symptoms occurring on 2 or more consecutive days
   Seemungal *et al.*, 2000 \[[@B69]\]        Presence for at least 2 consecutive days of an increase in any two major symptoms or an increase in one major and one minor symptom
  Treatment and symptoms                      
   Seemungal *et al.*, 2008 \[[@B70]\]        Sustained worsening of baseline respiratory symptoms for at least 2 days that required treatment with oral corticosteroids and/or antibiotics
   Tashkin *et al.*, 2008 \[[@B71]\]          Increase or new onset of more than one respiratory symptom (cough, sputum, sputum purulence, wheezing or dyspnea) lasting 3 days or more and requiring treatment with an antibiotic or a systemic corticosteroid
   Calverley *et al.*, 2008 \[[@B72]\]        Clinically significant worsening of COPD symptoms requiring treatment with antibiotics and/or systemic steroids
   Wedzicha *et al.*, 2008 \[[@B73]\]         Symptom worsening that required treatment with oral corticosteroids and/or antibiotics or required hospitalization
   Dusser *et al.*, 2006 \[[@B74]\]           Onset of at least one clinical descriptor (worsening of dyspnea, cough or sputum production, appearance of purulent sputum, fever (\>38°C), appearance of a new chest radiograph abnormality) lasting ≥2 days and requiring a new prescription or an increase in the dose of β~2~-agonists, antibiotics, corticosteroids or bronchodilators
   Soler-Cataluña *et al.*, 2005 \[[@B55]\]   Sustained increase in respiratory symptomatology compared with baseline requiring modification of regular medication and hospital treatment (acute exacerbation of COPD)
   Oostenbrink *et al.*, 2004 \[[@B75]\]      Complex of respiratory symptoms (new onset or worsening of more than one symptom such as cough, sputum, dyspnea or wheeze) lasting for ≥3 days
   Brusasco *et al.*, 2003 \[[@B76]\]         Complex of respiratory symptoms (new onset or an increase in at least one of the following: cough, sputum, dyspnea, wheeze, chest discomfort) lasting at least 3 days and usually associated with therapeutic intervention
  Model                                       
   Borg *et al.*, 2004 \[[@B77]\]             Increase in any two major symptoms (dyspnea, sputum purulence, sputum amount) or an increase in one major and one minor symptom (wheeze, sore throat, cough, and symptoms of a common cold, which were nasal congestion and/or discharge) for at least 2 consecutive days
  Not defined                                 
   Detournay *et al.*, 2004 \[[@B53]\]        ND

^a^Criteria used to define exacerbations were symptoms, treatment, symptoms and treatment or model-based. COPD stages are defined according to GOLD \[[@B53],[@B55],[@B59]-[@B62],[@B66]-[@B69],[@B74]-[@B77],[@B90]\], BTS \[[@B61]\] and SPLF \[[@B53]\] criteria. ^b^These three articles concern the same patients (the Inhaled Steroids in Obstructive Lung Disease trial). ^c^Healthcare-based definition of exacerbation corresponds to the \"treatment and symptoms\"-based definition. Abbreviations used: COPD, chronic obstructive pulmonary disease; BTS, British Thoracic Society classification; GOLD, Global Obstructive Lung Disease classification; SPLF, Société de Pneumonologie de Langue Française classification.

###### 

COPD exacerbations^a^

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exacerbation definition group\                   Country (sample size)           Classification\   Mean number of\              Treatment
  **(study type**^**b**^**)**                                                      (stage of COPD)   exacerbations per patient\   
                                                                                                     **and per year**^**c**^      
  ------------------------------------------------ ------------------------------- ----------------- ---------------------------- ----------------------------
  Treatment                                                                                                                       

   Burge *et al.*, 2003 \[[@B58]\]^d^(CT)          United Kingdom (524)            GOLD (2 or 3)     1.6-1.7                      Placebo

                                                                                                     1.1-1.4                      Fluticasone propionate

   Calverley *et al.*, 2003 \[[@B59]\] (CT)        25 countries (1,974)            GOLD (2 or 3)     1.3                          Placebo

                                                                                                     1.0                          Salmeterol

                                                                                                     1.0                          Fluticasone

                                                                                                     1.0                          Salmeterol and fluticasone

   Jones *et al.*, 2003 \[[@B60]\]^d^(CT)          United Kingdom (751)            GOLD (1 or 2)     1.0                          Placebo

                                                                                                     0.7                          Fluticasone

                                                                                   GOLD (3 or 4)     1.7                          Placebo

                                                                                                     1.5                          Fluticasone

   Andersson *et al.*, 2002 \[[@B61]\] (CT)        Sweden (191)                    GOLD/BTS          1.2                          

   Burge *et al.*, 2000 \[[@B62]\]^d^(CT)          United Kingdom (751)            GOLD (2 or 3)     1.9 (2.6)                    Placebo

                                                                                                     1.4 (1.9)                    Fluticasone

  Symptoms                                                                                                                        

   Effing *et al.*, 2009 \[[@B63]\] (CT)           Netherlands (142)               GOLD (2 or 3)     3.5 (2.7)                    

   Worth *et al.*, 2009 \[[@B64]\]^e^(CT)          Germany (220)                   GOLD (3 or 4)     0.9                          Placebo

                                                                                                     0.4                          Cineole

   Schermer *et al.*, 2009 \[[@B65]\] (CT)         Netherlands (286)               GOLD (1-3)        0.7                          Placebo

                                                                                                     0.9                          Fluticasone

                                                                                                     1.0                          *N*-acetylcysteine

                                                                                                                                  

   O\'Reilly *et al.*, 2006 \[[@B66]\] (OS)        United Kingdom (309)            GOLD (1 or 2)     2.2 \[1.9-2.7\]              Symptom-defined

                                                                                                     2.3 \[2.0-2.8\]              Healthcare-defined

                                                                                   GOLD (3 or 4)     2.5 \[2.1-2.9\]              Symptom-defined

                                                                                                     3.2 \[2.8-3.7\]              Healthcare-defined

   Wilkinson *et al.*, 2006 \[[@B67]\] (OS)        United Kingdom (74)             GOLD (2 or 3)     2.5 {1.3-3.8}                

   Donaldson *et al.*, 2003 \[[@B68]\] (OS)        United Kingdom (132)            GOLD (2 or 4)     2.5 {1.3-3.9}                

   Seemungal *et al.*, 2000 \[[@B69]\] (OS)        United Kingdom (101)            GOLD (2 or 4)     2.4 {1.3-3.8}                

                                                                                                                                  

  Treatment and symptoms                                                                                                          

   Seemungal *et al.*, 2008 \[[@B70]\] (CT)        United Kingdom (109)            GOLD (2 or 3)     2.0                          Placebo

                                                                                                     1.0                          Erythromycin

   Tashkin *et al.*, 2008 \[[@B71]\] (CT)          37 countries (5,993)            GOLD (2-4)        0.8                          Placebo

                                                                                                     0.7                          Tiotropium

   Calverley *et al.*, 2008 \[[@B72]\] (CT)        11 countries (911)              GOLD (2 or 3)     1.0                          Placebo

                                                                                                     0.6                          Mometasone furoate

   Wedzicha *et al.*, 2008 \[[@B73]\] (CT)         20 countries (1,323)            GOLD (3 or 4)     1.3                          SFC

                                                                                                     1.3                          Tiotropium

   Dusser *et al.*, 2006 \[[@B74]\] (CT)           France (1,010)                  GOLD (1 or 2)     2.0                          Placebo

                                                                                                     1.2                          Tiotropium

                                                                                   GOLD (3 or 4)     1.8                          Placebo

                                                                                                     2.7                          Tiotropium

   Soler-Cataluña *et al.*, 2005 \[[@B55]\] (OS)   Spain (304)                     GOLD (1)          (75, 25, 00)^f^              

                                                                                   GOLD (2)          (60, 35, 05)^f^              

                                                                                   GOLD (3)          (56, 32, 12)^f^              

                                                                                   GOLD (4)          (34, 40, 26)^f^              

   Oostenbrink *et al.*, 2004 \[[@B75]\] (CT)      Netherlands and Belgium (519)   GOLD (1-4)        1.0 (0.1)                    Placebo

                                                                                                     0.7 (0.1)                    Fluticasone

   Brusasco *et al.*, 2003 \[[@B76]\] (CT)         18 countries (1,207)            GOLD (2 or 3)     1.5                          Placebo

                                                                                                     1.2                          Salmeterol

                                                                                                     1.1                          Tiotropium

                                                                                                                                  

  Model                                                                                                                           

   Borg *et al.*, 2004 \[[@B77]\] (M)              Netherlands                     GOLD (1)          (0.05, 0.07, 0.01)^g^        

                                                                                   GOLD (2)          (1.01, 1.31, 0.14)^g^        

                                                                                   GOLD (3)          (1.06, 1.45, 0.17)^g^        

                                                                                   GOLD (4)          (1.47, 1.72, 0.33)^g^        

                                                                                                                                  

  Not defined                                                                                                                     

   Detournay *et al.*, 2004 \[[@B53]\] (OS)        France (255)                    Moderate          1.7                          

                                                                                   Moderate to       1.5                          

                                                                                   severe                                         

                                                                                   Severe            2.0                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Criteria used to define exacerbations were symptoms, treatment, symptoms and treatment or model-based. COPD stages are defined according to GOLD \[[@B53],[@B55],[@B59]-[@B62],[@B66]-[@B69],[@B74]-[@B77],[@B90]\], BTS \[[@B61]\] and SPLF \[[@B53]\] criteria. ^b^Study type reported as CT, clinical trial; OS, observational study; M, model. ^c^Mean numbers of exacerbations per person and per year were reported in various ways: mean exacerbation or mean exacerbation (±SD) or mean exacerbation {min-max} or \[95% confidence interval\]. ^d^These three articles concern the same patients (the Inhaled Steroids in Obstructive Lung Disease trial). ^e^These estimates are based on 6 months of follow-up. The mean exacerbation in both groups during the previous year was 3.2. ^f^This article does not give the mean number of exacerbations but the proportion of patients who had, respectively, no acute exacerbations, one, two or three or more. ^g^Mean number of exacerbations per person and per year reported separately for mild, moderate and severe exacerbations. Abbreviations used: COPD, chronic obstructive pulmonary disease; BTS, British Thoracic Society classification; GOLD, Global Obstructive Lung Disease classification; SPLF, Société de Pneumonologie de Langue Française classification; SFC, salmeterol and fluticasone propionate (anti-inflammatory drug combination); ISOLDE, the Inhaled Steroids in Obstructive Lung Disease trial.

Mortality
---------

As shown in Table [5](#T5){ref-type="table"} (see also a graph of these data in Additional file [3](#S3){ref-type="supplementary-material"}, Figure A3), reported estimates of COPD mortality in the general population vary from one country to another, but data interpretation must be done carefully. First, the International Classification of Diseases (ICD) has evolved with time, and the underlying classification or codes used for estimating mortality (for example, Hurd *et al.*\[[@B78]\] included codes 495 and 496 corresponding to asthma) are never similar from one study to another. Overall, mortality estimates have increased with time. However, increases in COPD mortality and features related to coding of mortality may both be involved in this increase, with relative parts hardly quantifiable. At present, the fairest comparison between countries should be made with 2007 European COPD-related mortality estimates issued by Eurostat \[[@B10]\]. The estimates ranged from 7.2 per 100,000 inhabitants in France to 36.1 per 100,000 inhabitants in Hungary, and mortality was between 1.3 (Sweden) and 13 (Malta) times higher in men than in women. Mortality estimates among hospital inpatients are high, as expected, at around 25% \[[@B79],[@B80]\] or even higher in patients with comorbidities \[[@B81]\]. The mortality of hospitalized patients with COPD increases with the number of exacerbations: In the study by Soler-Cataluña *et al.*\[[@B55]\], patients with 0, 1 or 2 and 3 or more acute COPD exacerbations per year had 36-month survival probabilities of 0.86, 0.70 and 0.42, respectively.

###### 

COPD age-standardized mortality rates^a^

  ------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       Annual mortality rate\                    
                                                                                       (per 100,000 inhabitants)                 
  ------------------------------------------ ---------------- ----------- ------------ --------------------------- ------ ------ -----------------------
  General population                                                                                                             

   Eurostat^b,c^\[[@B10]\]                   Austria          2007                     19.4                        30.8   12.1   ICD 10 (J40-J44, J47)

                                             Bulgaria                                  15.8                        26.7   07.9   

                                             Cyprus                                    09.3                        15.5   04.7   

                                             Czech Republic                            14.7                        24.1   08.5   

                                             Estonia                                   10.7                        24.2   04.4   

                                             Finland                                   12.9                        25.3   05.4   

                                             France                                    07.2                        12.5   03.8   

                                             Germany                                   16.3                        24.9   10.8   

                                             Greece^d^                                 10.9                        14.8   07.9   

                                             Hungary                                   36.1                        56.5   23.6   

                                             Lithuania                                 22.4                        49.0   08.5   

                                             Latvia                                    09.7                        22.4   03.0   

                                             Malta                                     16.0                        35.4   02.7   

                                             Netherlands                               26.0                        39.6   18.7   

                                             Poland                                    16.8                        32.0   07.8   

                                             Romania                                   20.6                        33.8   11.4   

                                             Spain                                     18.4                        37.1   06.1   

                                             Sweden                                    15.1                        17.6   13.6   

                                             Slovakia                                  12.8                        24.5   05.9   

                                             Slovenia                                  13.2                        23.4   07.5   

                                             United Kingdom                            28.4                        35.5   23.7   

   Hurd *et al.*, 2000 \[[@B78]\]            Austria          1997        35-74                                    32     6      ICD 9 (490-496)

                                             Bulgaria         1994                                                 38     8      

                                             France           1995                                                 26     5      

                                             Germany          1997                                                 28     11     

                                             Greece           1996                                                 12     1      

                                             Hungary          1995                                                 75     23     

                                             Italy            1993                                                 30     4      

                                             Netherlands      1995                                                 43     15     

                                             Poland           1996                                                 43     8      

                                             Portugal         1996                                                 38     7      

                                             Romania          1996                                                 61     18     

                                             Spain            1995                                                 45     6      

                                             Sweden           1996                                                 22     12     

                                             United Kingdom   1997                                                 48     31     

   Siafakas *et al.*, 1995 \[[@B45]\]        Austria          1988-1991   NS                                       18     6      ICD 9 (490-493)

                                             Belgium                                                               28     9      

                                             Bulgaria                                                              11     6      

                                             Denmark                                                               34     20     

                                             Finland                                                               22     4      

                                             France                                                                10     3      

                                             Greece                                                                03     2      

                                             Hungary                                                               40     16     

                                             Italy                                                                 25     8      

                                             Netherlands                                                           20     5      

                                             Poland                                                                29     8      

                                             Portugal                                                              14     5      

                                             Romania                                                               20     12     

                                             Spain                                                                 10     3      

                                             Sweden                                                                11     5      

                                             United Kingdom                                                        12     6      

  Hospital population^e^                                                                                                         

   Gudmundsson *et al.*, 2006^f^\[[@B81]\]   SweNorFin^g^     2002        72.1 ± 8.7   293                                       ICD 10 (J40-J47)

   Groeneweger *et al.*, 2003^h^\[[@B79]\]   Netherlands      2001        70.6 ± 8.5   230                                       COPD-ATS

   Almagro *et al.*, 2002^i^\[[@B80]\]       Spain            1999        72.0 ± 9     220                                       COPD^j^
  ------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Age was reported in various ways: mean age (±SD), or age range, min-max.^b^Not all European countries have COPD mortality data for 2007 in the Eurostat database. ^c^Total population (all ages). ^d^Greece does not have mortality data for asthma in 2007; these estimates correspond to J40-J47 and not to J40-J44, J47. ^e^Mortality rates in inpatients are of course not age-standardized but represent the number of deaths per 100,000 inhabitants. ^f^Mortality rates at 1 year for stages GOLD 1 and GOLD 2, GOLD 3, and GOLD 4 are 3.6, 6.9, and 13.7, respectively. ^g^This study concerned Sweden, Norway and Finland. ^h^Mortality rate at 6 months was 18. ^i^Mortality rates at 6 and 24 months were, respectively, 13.4 and 35.6. ^j^Clinical diagnosis of COPD and forced spirometry at discharge showing FEV~1~\<70% of the reference value and FEV~1~/FVC ratio \<70%. Abbreviations used: ICD, International Classification of Diseases. COPD-ATS, chronic obstructive pulmonary disease as defined by the American Thoracic Society; NS, not specified; GOLD, Global Obstructive Lung Disease classification stage; FEV~1~, maximum expiratory volume in 1 second; FVC, forced vital capacity.

Discussion
==========

This study describes the variability of reported COPD epidemiological data in European countries. Although the search of documents was limited to the WOS and Eurostat databases, the collected information was sufficient to outline how international standardization of research methodology has evolved over time and has contributed to estimates of better quality. In that regard, whereas documents not included in the present study, such as unpublished information, might be available through national health surveys or other initiatives, their additional value to this study is likely to be low.

As shown, one of the main reasons for the variability of the reported epidemiological estimates is the use of different methods by different authors, hindering valid comparisons. For example, prevalence estimates were based on a wide variety of methods (for example, symptoms, physician reports, spirometry, models), different populations (for example, general population, hospital inpatients), different age distributions and different definitions of COPD. Studies based on a small number of patients and on interviews (symptoms or physician reports) are not as reliable as larger studies based on spirometry. Methods based on symptoms are neither specific nor sensitive for the diagnosis of COPD. The use of a screening questionnaire (and questionnaires may also vary from one study to another) does not allow thorough investigation of the specific characteristics of the patients, and the lack of functional investigations means that questions on progression from cough and sputum production to airflow obstruction remain unanswered \[[@B15]\]. The same applies to studies based on physician reports. Thus, in a study of a given general population sample, the estimated prevalence is, respectively, 5.6% and 26.1%, depending on whether one uses physician reports or spirometry \[[@B19]\]. The use of different severity scales is another important source of heterogeneity \[[@B19]\]. For example, among 212 patients included in the Obstructive Lung Disease in Northern Sweden surveys, 179 had COPD in the BTS classification, whereas all had COPD on the basis of the GOLD 2006 criteria, including patients with FEV~1~≥80% of the predicted level (mild form) \[[@B49]\]. Because of these methodological problems and imprecise definitions, the terms *chronic bronchitis*and *chronic obstructive pulmonary disease*often were not differentiated in the past. However, these methodological limitations do not entirely explain the observed epidemiological variability. Other factors such as smoking and age probably contribute to the observed variability. A recent study considering COPD patients randomly selected from registers in a Swedish region indicated that only 59% had an initial diagnosis that involved spirometry \[[@B82]\], and in fact only longitudinal studies of young populations could allow early diagnosis and refine our knowledge of the natural history of COPD. In the recent largest international study on COPD, the BOLD study, prevalence data based on spirometry according to GOLD guidelines were collected at 12 sites in different countries, 5 of which were located in Europe \[[@B8]\]. Interestingly, these prevalence estimates are within the same range as those reported in the PLATINO study of five Latin American countries \[[@B9]\]. These results likely reflect the benefits of the international standardization of methodology. Nevertheless, the BOLD study reported significant differences across the different sites (*P*\< 0.0001), but the authors underlined the danger of extrapolating data from such sites (a pool of about 150,000 people) to national populations. Therefore, the present national prevalence estimates that may be twice those from one European country to another (Table [1](#T1){ref-type="table"}) should still be considered with caution.

As observed with regard to prevalence, a large epidemiological variability is observed with respect to COPD severity, but our study indicates that severity is the parameter for which recent standardization has resulted in the best improvement of estimates. Besides, severity is a very active research domain. In recent years, several composite scores, such as the BODE index (body mass index, airflow obstruction, dyspnea and exercise capacity), ADO index (age, dyspnea and airflow obstruction) or the DOSE index (dyspnea, airflow obstruction, smoking status and exacerbation frequency) \[[@B83],[@B84]\], have been proposed for grading patients\' disease severity. At present, the GOLD severity scale is the international standard, and our results indicate that recent estimates from the international studies based on this classification generally represent relatively low differences in the distribution of severity from one country to another within a given type of population.

This situation contrasts with the reported data on exacerbations for which the GOLD initiative did not recommend methodological guidelines. Unsurprisingly, exacerbation data clearly indicate that severe COPD is associated with more frequent and more severe exacerbations, but estimates of the frequency of exacerbations depend largely on the definition used \[[@B59],[@B66],[@B76]\]. Exacerbations are variously defined as a complex of respiratory symptoms or as a complex of respiratory symptoms requiring steroid or antibiotic treatment (Table [4](#T4){ref-type="table"}). The influence of age and smoking status on exacerbations is poorly documented. The main COPD management objective is currently to prevent exacerbations. Most estimates concerning exacerbations come from therapeutic trials, which focus on selected populations and in which the frequency of exacerbations is used to judge treatment efficacy. As underlined by Aaron *et al.*\[[@B85]\], standardizing counts, analyses and method of reporting exacerbations are of major importance for a fair evaluation of treatments tested in randomized controlled trials.

Although several studies have reported COPD mortality data \[[@B45],[@B78]-[@B81]\], the mortality data in the general population issued by Eurostat are those allowing the most standardized comparison between countries. The ICD is an international standard for categorizing mortality data, but the reliability of mortality estimates is undermined by problems of coding \[[@B86]\]. In addition, since some researchers think that there is a considerable overlap between asthma and COPD in adults, some COPD mortality estimates may be overestimated. Conversely, COPD mortality is also underreported \[[@B87]\], and causes of death remain to be standardized among patients with several comorbidities \[[@B16]\]. It may be difficult to get a great deal of consistency, because patients with COPD often do not die as a result of acute exacerbations of COPD or respiratory failure. More often they die as a result of cardiovascular causes, cancer, pneumonia and other related conditions. It can be challenging and difficult to decide which ICD code to use in recording the death certificate. More work is needed to come up with a realistic method of assessing the mortality rate in COPD. Finally, observed variations in COPD mortality rates across countries include variations in performance of the local healthcare systems with respect to COPD patient management, but indicators permitting such comparisons in specific settings are lacking.

The difficulties in comparing COPD studies outlined in this review can be attributed to two distinct reasons. First, the methodological bases may vary from one study to another, such as the definition of COPD. Nevertheless, our study also shows that efforts to establish congruence among COPD definitions and study methods are underway. Second, regardless of the methodology used for performing the study, the method of reporting results, such as exacerbation data, may vary from one report to another. This may also concern the reporting of important features related to the disease, such as smoking history. Smoking consumption (patients may be categorized in arbitrary classes of pack-year consumption) was used in some studies, whereas others used a three smoking status categorization (never smoker, former smoker, current smoker). There are current guidelines for reporting research, but they are based on the methodological type of the studies \[[@B88]\]. Our study strongly suggests that establishing reporting guidelines dedicated to COPD studies may constitute a major contribution to enhancing the value of COPD research and management by facilitating comparisons between studies.

Conclusions
===========

COPD is a major public health problem \[[@B89]\]. The wide range of prevalence, severity and mortality estimates across European countries cannot possibly correspond to real differences, but it remains difficult to assess the part of this heterogeneity due to methodological issues and the part of this heterogeneity due to countries\' characteristics, such as differences in national smoking exposure. National prevalence estimates are still far from perfect, impairing fair comparisons from one country to another. The present study outlines that with time, congruence of COPD definitions, especially in terms of severity classification, and methodological standardization have resulted in more comparable epidemiological estimates, but much remains to be made in terms of exacerbation data. Many international efforts have been made to develop common rules for coding mortality data, but they concern all diseases, and potential improvements of COPD mortality data are likely to poorly depend on specific COPD programs. Efforts to establish common standardized COPD definitions and study methods are underway, and researchers are encouraged to do more to better assess the disease and the relative effectiveness of methods of patient management in different European Union member states. In that regard, the establishment of international guidelines for reporting research on COPD may constitute an important contribution. Indeed, the present review strongly supports the use of commonly agreed guidelines for bringing more uniformity to the findings reported in future studies. Our results emphasize the need for scientists and investigators to work harder at adopting common guidelines that may be imperfect but nevertheless acceptable, so that the epidemiological database can be richer, the burden of the disease can be better defined and the response of patients with COPD to treatment can be better evaluated.
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